This demonstrated that the suppressive effect of decitabine on GPX4 activity was significantly reversed by Fer-1 and Z-VAD-FMK in low-risk MDS whereas antagonized by Fer-1 and necrostatin-1 in high-risk MDS (Figure 6F). Here, GPX4 is linked to myelodysplastic syndrome.